1. D. Zeitouni, Y. Pylayeva-Gupta, C.J. Der, K.L. Bryant, KRAS Mutant pancreatic cancer: No lone path to an effective treatment. Cancers (Basel). 18(8) (2016)
2. A.G. Stephen, D. Esposito, R.K. Bagni, F. McCormick, Dragging ras back in the ring. Cancer Cell. 25, 272–281 (2014)
3. P. Lito, A. Saborowski, J. Yue, M. Solomon, E. Joseph, S. Gadal, M. Saborowski, E. Kastenhuber, C. Fellmann, K. Ohara, K. Morikami, T. Miura, C. Lukacs, N. Ishii, S. Lowe, N. Rosen, Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 25, 697–710 (2014)
4. M. Malumbres, I. Pérez de Castro, Aurora kinase A inhibitors: promising agents in antitumoral therapy. Expert. Opin. Ther. Targets. 18, 1377–1393 (2014)
5. A. Tang, K. Gao, L. Chu, R. Zhang, J. Yang, J. Zheng, Aurora kinases: novel therapy targets in cancers. Oncotarget. 8, 23937–23954 (2017)